SerumPro-Oxidant-Antioxidant Balance, Advanced Oxidized Protein Products (AOPP) and Protein Carbonyl in PatientsWith Stroke


1 Department of Biochemistry, Biochemistry and Nutrition Research Center, Faculty of Medicine,Mashhad University of Medical Sciences,Mashhad, IR Iran

2 Department of Neurology, GhaemHospital,Mashhad University of Medical Sciences,Mashhad, IR Iran

3 Biochemistry of Nutrition Research Center,Mashhad University of Medical Sciences,Mashhad, IR Iran

4 Surgical Oncology Research Center, ImamReza Hospital, Faculty of Medicine,Mashhad University of Medical Sciences,Mashhad, IR Iran

5 Department of Biochemistry, Faculty of Medicine,Mashhad University of Medical Sciences,Mashhad, IR Iran


Abstract Background: Stroke is the second cause of death and disability in the world, and oxidative stress which could be considered as a prognostic factor in patients for prevention, follow up and determination of stroke’s severity has a conceivable role in neural damage. Objectives: The aim of our study was to explain the association between oxidant/antioxidant imbalance as a prognostic factor in patients with stroke. Patients and Methods: Pro-oxidant-antioxidant balance (PAB), advanced oxidized protein products (AOPP) and protein carbonyl were measured in patients with ischemic stroke and hemorrhagic stroke as well as healthy group. Sera were collected from 18 is- chemic and 23 hemorrhagic stroke patients, and 34 healthy volunteers. The PAB assay, routine biochemical parameters, lipid profile and total protein concentration were assessed in patients and healthy group. Results: The level of AOPP (P < 0.007), protein carbonyl (P < 0.001) and PAB (P < 0.01) were significantly higher in stroke patients than the healthy group. Conclusions: There are increased level of protein carbonyl, AOPP and PAB in patients with stroke. Measuring these factors may be beneficial as prognostic factors in treatment and follow up of the patients with both hemorrhagic and ischemic strokes. More investigations withmore cases and longer follow up are needed to approve that these factors play an important role in prognosis of stroke.


  1. 1.Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354(9188):1457–63. doi: 10.1016/S0140-6736(99)04407-4. [PubMed: 10543686].

    1. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000;31(7):1588–601. [PubMed: 10884459].
    2. Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke. 2002;33(11):2718–21. [PubMed: 12411667].
    3. Kothari R, Sauerbeck L, Jauch E, Broderick J, Brott T, Khoury J, et al. Patients’ awareness of stroke signs, symptoms, and risk factors. Stroke. 1997;28(10):1871–5. [PubMed: 9341687].
    4. Goszcz K, Deakin SJ, Duthie GG, Stewart D, Leslie SJ, Megson IL. Antioxidants in Cardiovascular Therapy: Panacea or False Hope?. Front Cardiovasc Med. 2015;2:29. doi: 10.3389/fcvm.2015.00029. [PubMed: 26664900].
    5. Goldstein LB, Amarenco P, Szarek M, Callahan A3, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 Pt 2):2364–70. doi: 10.1212/01.wnl.0000296277.63350.77. [PubMed: 18077795].
    6. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989;20(11):1460–5. [PubMed: 2815179].
    7. Gibbons GH. Collaborative partnership model results in new cardiovascular disease prevention guidelines. NHLBI; 2013.
    8. El Kossi MM, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stroke. Stroke. 2000;31(8):1889–92. [PubMed: 10926952].
    9. Parizadeh MR, Azarpazhooh MR, Mobarra N, Nematy M, Alamdari DH, Tavalaie S, et al. Prooxidant-antioxidant balance in stroke patients and 6-month prognosis. Clin Lab. 2011;57(3-4):183–91. [PubMed: 21500725].
    10. Lucivero V, Prontera M, Mezzapesa DM, Petruzzellis M, Sancilio M, Tinelli A, et al. Different roles of matrix metalloproteinases-2 and - 9 after human ischaemic stroke. Neurol Sci. 2007;28(4):165–70. doi: 10.1007/s10072-007-0814-0. [PubMed: 17690845].
    11. Polidori MC, Frei B, Cherubini A, Nelles G, Rordorf G, Keaney JJ, et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol Med. 1998;25(4-5):561–7. [PubMed: 9741593].
    12. Dominguez C, Delgado P, Vilches A, Martin-Gallan P, Ribo M, Santamarina E, et al. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke. 2010;41(4):653–60. doi: 10.1161/STROKEAHA.109.571935. [PubMed: 20185784].
    13. Betteridge DJ. What is oxidative stress?. Metabolism. 2000;49(2 Suppl 1):3–8. [PubMed: 10693912].
    14. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37(5):471–80. [PubMed: 12797466].
    15. Piantadosi CA, Zhang J. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat. Stroke. 1996;27(2):327–31. [PubMed: 8571432] discussion 32.
    16. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J. 2007;401(1):1–11. doi: 10.1042/BJ20061131. [PubMed: 17150040].
    17. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis. 2007;12(5):913–22. doi: 10.1007/s10495- 007-0756-2. [PubMed: 17453160].
    18. Paschen W. Endoplasmic reticulum dysfunction in brain pathology: critical role of protein synthesis. Curr Neurovasc Res. 2004;1(2):173–81. [PubMed: 16185192].
    19. Murakami K, Kondo T, Kawase M, Li Y, Sato S, Chen SF, et al. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci. 1998;18(1):205–13. [PubMed: 9412501].
    20. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology. 2000;7(3):153–63. [PubMed: 10996508].
    21. Kong SY, Goodman M, Judd S, Bostick RM, Flanders WD, McClellan W. Oxidative balance score as predictor of all-cause, cancer, and noncancer mortality in a biracial US cohort. Ann Epidemiol. 2015;25(4):256–62 e1. doi: 10.1016/j.annepidem.2015.01.004. [PubMed: 25682727].
    22. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006;132(1):108–13. doi: 10.1111/j.1365- 2141.2005.05834.x. [PubMed: 16371026].
    23. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2015 doi: 10.1016/j.jsps.2015.03.013.
    24. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol. 2008;23(3):381–90. [PubMed: 18072094].
    25. Pohanka M. Alzheimer s disease and oxidative stress: a review. Curr Med Chem. 2014;21(3):356–64. [PubMed: 24059239].
    26. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181–90. doi: 10.1152/ajpheart.00554.2011. [PubMed: 21949114]. Razavi Int J Med. 2016; 4(2):e38203. 5 Toloue Pouya V et al.
    27. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18(6):655–73. [PubMed: 10872549].
    28. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80(6):1611–7. [PubMed: 15585776].
    29. Pilch W, Szygula Z, Tyka AK, Palka T, Tyka A, Cison T, et al. Disturbances in pro-oxidant-antioxidant balance after passive body overheating and after exercise in elevated ambient temperatures in athletes and untrained men. PLoS One. 2014;9(1):ee85320. doi: 10.1371/journal.pone.0085320. [PubMed: 24465535].
    30. Schauenstein E, Esterbauer H. Formation and properties of reactive aldehydes. Ciba Found Symp. 1979;67:225–44. doi: 10.1002/9780470720493.ch15.
    31. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11(1):81–128. [PubMed: 1937131].
    32. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994;233:346–57. [PubMed: 8015469].
    33. Alamdari DH, Ghayour-Mobarhan M, Tavallaie S, Parizadeh MR, Moohebati M, Ghafoori F, et al. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem. 2008;41(6):375–80. doi: 10.1016/j.clinbiochem.2007.12.008. [PubMed: 18191639].
    34. Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta. 2004;1689(2):91–102. doi: 10.1016/j.bbadis.2004.02.008. [PubMed: 15196590].
    35. Eghwrudjakpor PO, Allison AB. Oxidative stress following traumatic brain injury: enhancement of endogenous antioxidant defense systems and the promise of improved outcome. Niger J Med. 2010;19(1):14–21. [PubMed: 20232751].
    36. Malhotra R, Lin Z, Vincenz C, Brosius F3. Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. Am J Physiol Cell Physiol. 2001;281(5):C1596–603. [PubMed: 11600423].
    37. Weilinger NL, Maslieieva V, Bialecki J, Sridharan SS, Tang PL, Thompson RJ. Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction. Acta Pharmacol Sin. 2013;34(1):39–48. doi: 10.1038/aps.2012.95. [PubMed: 22864302].
    38. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab. 1998;18(1):2–25. doi: 10.1097/00004647-199801000- 00002. [PubMed: 9428302].
    39. Cao XL, Du J, Zhang Y, Yan JT, Hu XM. Hyperlipidemia exacerbates cerebral injury through oxidative stress, inflammation and neuronal apoptosis in MCAO/reperfusion rats. Exp Brain Res. 2015;233(10):2753– 65. doi: 10.1007/s00221-015-4269-x. [PubMed: 26238404].
    40. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med. 2005;38(11):1433–44. doi: 10.1016/j.freeradbiomed.2005.01.019. [PubMed: 15890617].
    41. Simao AN, Lehmann MF, Alfieri DF, Meloni MZ, Flauzino T, Scavuzzi BM, et al. Metabolic syndrome increases oxidative stress but does not influence disability and short-time outcome in acute ischemic stroke patients. Metab Brain Dis. 2015;30(6):1409–16. doi: 10.1007/s11011-015- 9720-y. [PubMed: 26342606].
    42. Nilsson GE, Lutz PL. Anoxia tolerant brains. J Cereb Blood Flow Metab. 2004;24(5):475–86. doi: 10.1097/00004647-200405000-00001. [PubMed: 15129179].
    43. Arslan C, Altan H, Besirli K, Aydemir B, Kiziler AR, Denli S. The role of oxidative stress and antioxidant defenses in Buerger disease and atherosclerotic peripheral arterial occlusive disease. Ann Vasc Surg. 2010;24(4):455–60. doi: 10.1016/j.avsg.2008.11.006. [PubMed: 19128930].
    44. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med. 2005;39(7):841–52. doi: 10.1016/j.freeradbiomed.2005.06.025. [PubMed: 16140205].
    45. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry. 2003;74(3):312–6. [PubMed: 12588914].
    46. Re G, Azzimondi G, Lanzarini C, Bassein L, Vaona I, Guarnieri C. Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. Eur J Emerg Med. 1997;4(1):5–9. [PubMed: 9152688]. 48. Belch J, McLaren M, Hanslip J, Hill A, Davidson D. The white blood cell and plasma fibrinogen in thrombotic stroke. A significant correlation. Int Angiol. 1998;17(2):120–4. [PubMed: 9754901].
    47. Pena-Sanchez M, Riveron-Forment G, Zaldivar-Vaillant T, SotoLavastida A, Borrero-Sanchez J, Lara-Fernandez G, et al. Association of status redox with demographic, clinical and imaging parameters in patients with Huntington’s disease. Clin Biochem. 2015;48(18):1258–63. doi: 10.1016/j.clinbiochem.2015.06.014. [PubMed: 26210848].
    48. Siciliano G, Piazza S, Carlesi C, Del Corona A, Franzini M, Pompella A, et al. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J Neurol. 2007;254(5):575–80. doi: 10.1007/s00415-006-0301-1. [PubMed: 17426914].
    49. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis. 2002;162(1):221–5. [PubMed: 11947918].
    50. Kalousova M, Zima T, Tesar V, Sulkova S, Fialova L. Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int Suppl. 2003(84):S62–4. doi: 10.1046/j.1523-1755.63.s84.19.x. [PubMed: 12694311].
    51. Cichon N, Bijak M, Miller E, Niwald M, Saluk J. Poststroke depression as a factor adversely affecting the level of oxidative damage to plasma proteins during a brain stroke. Oxid Med Cell Longev. 2015;2015:408745. doi: 10.1155/2015/408745. [PubMed: 25838867].
    52. Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol. 2014;10(2):140–7. doi: 10.3988/jcn.2014.10.2.140. [PubMed: 24829600].